BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target. Investors immediately soured on Wednesday’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

A first from Ultragenyx in a rare disease  FDA approved Crysvita burosumab-twza from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat tumor-induced osteomalacia in patients age two and older. The anti-FGF23 mAb is the first to be...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

Protein degradation company C4 and gene therapy play 4D Molecular each raised venture rounds that included crossover investors, suggesting each company could soon join an IPO queue that has burgeoned in recent weeks. 4D had...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Jun 8, 2020
Product Development

COVID-19 mAb supplies could fall short of demand

Regeneron and Vir will soon start clinical trials of mAbs to treat and prevent COVID-19, but both companies are warning that manufacturing capacity constraints could limit access. Speaking at the BIO International Convention, George Yancopoulos,...
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
Items per page:
1 - 10 of 4874
BioCentury | Jul 2, 2020
Finance

Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout

Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target. Investors immediately soured on Wednesday’s...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

A first from Ultragenyx in a rare disease  FDA approved Crysvita burosumab-twza from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat tumor-induced osteomalacia in patients age two and older. The anti-FGF23 mAb is the first to be...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

Protein degradation company C4 and gene therapy play 4D Molecular each raised venture rounds that included crossover investors, suggesting each company could soon join an IPO queue that has burgeoned in recent weeks. 4D had...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Jun 8, 2020
Product Development

COVID-19 mAb supplies could fall short of demand

Regeneron and Vir will soon start clinical trials of mAbs to treat and prevent COVID-19, but both companies are warning that manufacturing capacity constraints could limit access. Speaking at the BIO International Convention, George Yancopoulos,...
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
Items per page:
1 - 10 of 4874